New antibody drug takes on advanced cancers in first human trial
Disease control
Ongoing
This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …
Phase: PHASE1 • Sponsor: Nectin Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC